Menu Search
Equities

Hologic Inc

HOLX:NSQ

Hologic Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)82.40
  • Today's Change0.68 / 0.83%
  • Shares traded1.41m
  • 1 Year change+14.41%
  • Beta0.9824
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy5
Outperform6
Hold8
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Hologic Inc have a median target of 88.00, with a high estimate of 96.00 and a low estimate of 78.00. The median estimate represents a 6.80% increase from the last price of 82.40.
High16.5%96.00
Med6.8%88.00
Low-5.3%78.00

Earnings history & estimates in USD

On Jul 29, 2024, Hologic Inc reported 3rd quarter 2024 earnings of 1.06 per share. This result was in line with the consensus of the 15 analysts following the company and exceeded last year's 3rd quarter results by 13.98%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+3.46%
Hologic Inc reported annual 2023 earnings of 3.96 per share on Nov 09, 2023.
Average growth rate+28.11%
More ▼

Revenue history & estimates in USD

Hologic, Inc. had 3rd quarter 2024 revenues of 1.01bn. This bettered the 1.00bn consensus of the 14 analysts covering the company. This was 5.85% below the prior year's 3rd quarter results.
Average growth rate+0.76%
Hologic, Inc. had revenues for the full year 2023 of 4.03bn. This was 17.12% below the prior year's results.
Average growth rate+7.63%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.